Objective: Tumour features were evaluated during intermittent androgen suppression (IAS), and their prognostic impact on the first off-treatment time was analysed. Patients and methods: Twenty patients with advanced prostate cancer underwent three consecutive prostate biopsies during the first cycle, namely at the beginning of androgen deprivation, 8 months after continuous therapy and at the time of prostate-specific antigen (PSA) progression above 20 ng/ml. Biopsy specimens were immunohistochemically processed and analysed for the apoptotic index (AI), Ki-67, p53 and Bcl-2 to investigate eventual changes over time. Correlations and regression analysis were performed to assess the prognostic significance of clinical and pathological parameters in predicting the first off-treatment time. Results: In contrast to the AI, p53 and Bcl-2, Ki-67 was the only marker that significantly changed over time (P ¼ 0.008). The first off-treatment time correlated significantly with pretreatment PSA (r ¼ À0.594; Po0.01), testosterone recovery time (r ¼ 0.590; P ¼ 0.013) and biopsy grade (r ¼ À0.738; Po0.01); only the latter gaining an independent factor in the multivariate analysis (P ¼ 0.022). Conclusions: During IAS, Ki-67 was the only molecular marker that consistently changed over time. However, it did not correlate with off-treatment time that was predicted independently by the initial biopsy grade only. First off-treatment time was best predicted by clinical parameters and molecular markers from needle biopsies did not further contribute to a better patient selection.
Introduction
Carcinoma of the prostate is the most common cancer in men. Although localized prostate cancer (PC) may be cured by radical prostatectomy, external beam radiation or even brachytherapy, the treatment of advanced or metastatic disease remains a challenge. Since 1941, when Huggins and Hodges 1 published their key study on androgen deprivation, hormone therapy represents the gold standard for such cases. However, neither surgical nor medical castration can cure PC, and progression to an androgen-independent state is almost inevitable. On the other hand, androgen deprivation has a variety of side effects such as anaemia, loss of libido, hot flushes, decreased muscle mass as well as osteoporosis with a distinct risk of bone fracture leading to prolonged immobilization. 2 In addition, quality of life may be hampered severely by fatigue and depression, which are frequently observed in patients under androgen deprivation. 3 During the past 15 years, intermittent androgen suppression (IAS) has repeatedly been suggested as a potential alternative treatment for various reasons. 4, 5 In experimental animal models, IAS seems to delay progression compared to continuous hormonal therapy. 6 Androgen withdrawal induces apoptotic regression of normal and malignant prostatic epithelial cells. However, androgen insensitivity of prostate cells develops during continuous androgen suppression mainly owing to the inability of dividing cells to re-differentiate and become pre-apoptotic again. To overcome this phenomenon, an incremental androgenic stimulus during the off-treatment period may recruit atrophic cells into a normal pathway of differentiation again. 7 In addition, recovery from side effects during off-treatment periods with improved quality of life has been emphasized.
The data available on IAS demonstrated that the length of treatment and off-treatment periods may vary widely, probably owing to differences in tumour biology and variations of testicular function recovery. However, studies focusing on changes in cell proliferation and apoptotic regression in PC during IAS have rarely been performed so far, although the knowledge of such prognostic factors would help to select the most appropriate candidates for IAS, that is, patients with prolonged off-treatment periods resulting in a substantial reduction of long-term side effects. The present phase II trial was designed to study common tumour cell proliferation markers during IAS as well as to analyse prognostic factors predicting the duration of the first off-treatment period.
Patients and methods

Patients
Men with previously untreated locally advanced or metastatic PC presenting with following criteria were included: palpable primary tumour allowing repeated biopsies, life expectancy of more than 1 year and prostate-specific antigen (PSA) levels of more than 20 ng/ml. Over a 2-year period, 35 patients were recruited by three centres. The trial was approved by the local ethical committee of each participating institution and all patients signed an informed consent for the use of individual data.
During the 8 months induction period, all patients received maximal androgen blockade (MAB) with goserelin acetate 3.6 mg subcutaneously every 4 weeks and the non-steroidal antiandrogen bicalutamide 50 mg once daily orally starting 1 week before the first administration of the GnRH analogue. Treatment was discontinued only in patients with a PSA reduction below 20 ng/ml and then followed monthly until PSA progression above 20 ng/ml. This represented the study end point and was met by 20 men eligible for evaluation. Patients not reaching a PSA nadir of less than 20 ng/ml (n ¼ 8) were excluded as were seven others who abandoned MAB owing to adverse events or were lost to follow-up.
Procedures
Serum PSA and total testosterone was measured before MAB, as well as after 4 and 8 months of therapy, respectively. After cessation of MAB, PSA and serum testosterone levels were assessed monthly. All serum PSA determinations were performed with the Abbott Axym assay (Abbott Park, IL, USA), and the serum testosterone determinations were performed with the EIAgen Testosterone kit (BioChem ImmunoSystems, Rome, Italy), respectively. Both serum analyses were carried out by one central laboratory (Mistelbach, General Hospital of Mistebach, Mistelbach, Austria). Testosterone recovery time was defined as the period between cessation of MAB and measurement of a testosterone value identical or most similar to the pretreatment level. Bone scans were routinely performed in all patients at study entry and after the 8 months induction phase. The performance status using the Eastern Cooperative Oncology Group (ECOG) score was assessed monthly. 8 Three systematic transrectal sextant biopsies of the prostate were performed: before therapy, after the 8 months induction phase as well as at the end of the study. Using a spring-loaded biopsy gun with an 18 G needle, specimens were taken in the parasagittal plane from the apex, the middle and the base of the right and left prostatic lobes.
Prostate biopsies were routinely fixed in buffered formalin and processed in paraffin. Diagnosis was performed by light microscopic examination of tissue sections stained with haematoxylin and eosin. Grading was performed according to the classification proposed by Mostofi et al. 9 To assess the apoptotic index (AI), the number of apoptotic bodies per 100 cells was counted.
Immunohistochemical analysis for p53, Ki67 and Bcl-2 was performed on formalin-fixed, paraffin-embedded sections using the labelled streptavidin-biotin (LSAB) method with the DAKO LSAB 2 Kit Peroxidase according to the manufacturer's instructions. Paraffin sections (5 mm) were mounted on coated slides (Vectabond TM Reagent, Vector Laboratories, CA, USA), deparaffinized, rehydrated and pretreated by boiling in 0.01 mol citrate puffer for 4 min. The endogenous peroxidase activity was blocked with hydrogen peroxide. We used the following primary antibodies and dilutions: monoclonal mouse anti-human p53 protein (DAKO, DO 7, code: M 7001, Denmark), 1:50; rabbit anti-human Ki-67 antigen (DAKO, MIB, code: A 0047, Denmark), 1:50; monoclonal mouse anti-human Bcl-2 oncoprotein (DAKO, clone 124, code: M 0887, Denmark), 1:50, respectively. The primary antibody was added, and slides were incubated for 30 min at room temperature.
The sections were incubated for 10 min with the secondary antibody followed by 10 min with streptavidin peroxidase. The chromogen diaminobenzidine (Abbott Laboratories, IL, USA) was developed and subsequently counterstained with haematoxylin for 30 s. Positive control sections consisted of tonsil for Bcl-2 and Ki-67, as well as breast carcinoma with a known p53 mutation. As negative controls, sections were stained in the usual manner using non-immune serum substituted for the primary antibody. The Ki-67 proliferation index was assessed by counting at least 1000 tumour cells or the total number of tumour cells if less than 1000 tumour cells were present at Â 400 magnification, and calculating the percentage of positive nuclei. A case was considered positive for p53 or Bcl-2 expression when staining was more than 5% by the corresponding antibody. All biopsy specimens were reviewed and processed centrally by one single pathologist (CF).
Statistics
Data were analysed using the SPSS package, Version 11.0. (SPSS Inc., Chicago, IL, USA). For intragroup changes of IAS, the Friedmann multiple comparison test was performed. Spearman's correlation coefficient analysis was applied to investigate the correlation between pathobiological variables and first off-treatment time. Probability for the first off-treatment time was calculated with the Kaplan-Meier method. Cox's regression analysis was performed for multivariate analysis of prognostic factors. A probability (P) level of less than 0.05 was considered statistically significant. All statistical tests were two-sided.
Results
Clinical and pathological characteristics
The mean age of the study cohort (n ¼ 20) was 67. 078.8 (median 68.0; 48-86) years. Patients showed an initial 
Proliferatsion marker profiles at different times of IAS
The results of the immunohistochemical analyses are summarized in Table 2 . The proliferation index Ki-67 showed a significant reduction after 8 months of MAB and at the time of PSA progression above 20 ng/ml (P ¼ 0.008). The patterns of AI, as well as p53 and Bcl-2 expression showed no significant difference between the initial biopsy and any time thereafter.
Prognostic markers for the first off-treatment time
On an average, all patients were off treatment 48.6% of the time during the first cycle. Kaplan-Meier analysis revealed a significant difference in off-treatment periods favouring well and moderately differentiated cancers (P ¼ 0.0004; log-rank test) (Figure 1 Table 4 . Only the grade of the initial biopsy remained an independent factor (P ¼ 0.022) for the duration of the first offtreatment period.
Discussion
For the treatment of advanced PC, the concept of IAS may have two possible advantages over continuous androgen deprivation. First, withdrawing therapy for at least some time may diminish side effects seen with continuous androgen deprivation, thus resulting in an improved quality of life.
10 This is particularly true for patients with a reasonable testosterone recovery time and, hence, prolonged off-treatment periods. A second advantage might result from a possibly better oncological outcome. Compared to continuous hormonal therapy, IAS seems to delay progression to a hormone-independent stage at least in experimental animal models. 6, 11 However, up to now, clinical phase III trials comparing continuous androgen deprivation with IAS failed to demonstrate a survival benefit. Nonetheless, comparable oncological results in terms of time to progression and survival together with fewer side effects and reduced costs for medical treatment may justify such an approach.
Previous studies primarily focused on the feasibility of IAS, but detailed analysis of prognostic factors are rare. [12] [13] [14] [15] Meanwhile, it became evident that at least some patients with advanced PC are not good candidates for IAS. Particularly, patients with short off-treatment periods will not benefit from IAS because of insufficient testosterone recovery time. The knowledge of prognostic factors might help to establish appropriate selection criteria. In our study, we focused on the relationship between patho-biological features such as AI, Ki-67, p53 and Bcl-2, and clinical outcome in order to predict prolonged off-treatment periods.
The Ki-67 antigen is a nuclear protein expressed during all phases of the cell cycle except G0 and a high proliferation rate was observed in hormone refractory cancer. 16 In patients undergoing radical prostatectomy, Paterson et al. 17 compared the initial needle biopsies with the surgical specimens after neoadjuvant hormonal therapy and reported a distinct decrease in Ki-67 staining. In our study, the expression of Ki-67 showed a significant reduction following 8 months of androgen suppression, which almost reached the initial level after cessation of hormonal therapy again. However, neither pretreatment nor post-treatment Ki-67 expression correlated with the duration of the first off-treatment period.
Studies have shown that androgen deprivation enhances apoptosis in PC. 18 After 8 months of androgen deprivation, we observed a trend towards a higher AI, which decreased again after cessation of hormonal therapy. However, the Friedmann test did not reveal a significant change between the different states of IAS. Accordingly, when analysing prostatectomy specimens, Miyata et al. 19 found a higher AI following 3-7 months of androgen deprivation, but no significant difference after 8-12 months.
The proto-oncogene Bcl-2, one of the most important regulators of cell growth, plays a crucial role in the regulation of apoptosis. 20 Increased expression is commonly seen in hormone-refractory disease and correlates with androgen independence. 21, 22 Enhanced staining for Bcl-2 in neoadjuvantly treated patients was also reported by Paterson et al. 17 Wild-type p53 has tumour-suppressing activity by inhibiting DNA-damaged cell proliferation. 23 Under normal circumstances, wild-type p53 is rapidly degraded. Immunohistochemical detection of p53 is an abnormal finding that may indicate a mutation in the TP53 gene. The expression of p53 correlates with tumour progression and prognosis. 24, 25 In our study, Bcl-2 and p53 did not show any significant change during IAS, nor did they correlate with the first offtreatment time. It remains unclear whether this reflects the unpredictable biological behaviour of hormonally treated advanced PC or is simply a shortcoming of our study. In fact, biomarker analysis from needle biopsies might be compromised by the inhomogeneous distribution of the marker expression within the prostatic tissue and we must be aware that the core of an 18 G needle only samples roughly 0.03% of the total gland tissue. 26 Klotz et al. 27 pursued another approach to predict the duration of the first off-treatment period. In patients with PSA progression after radiation therapy and consecutively treated with intermittent androgen deprivation therapy, these authors analysed the length of the CAG trinucleotide repeat polymorphism in the androgen receptor as possible predictor. However, they could not establish any relationship. Nonetheless, unlike biomolecular markers, some clinical and pathological characteristics seem to be able to identify patients with a prolonged off-treatment time. Patients with well or moderately differentiated tumours spend more than twice the time off therapy compared to those with poorly differentiated cancers, (Figure 1) . On an average, the proportion of off-treatment time within the first cycle was 58.8 versus 38.6% in favour of men with well or moderately differentiated cancers. This is in keeping with the current literature, reporting on off-treatment times in the cycles between 30 and 59%. 28 Pretreatment PSA and testosterone recovery time also correlated with off-treatment time, but in the multivariate analysis, only biopsy grade was independently significant. This is in contrast to the study of Goldenberg et al., 4 in which tumour grade did not affect off-treatment time. These authors also found no difference between patients with and without metastases. In contrast, de La Taille et al. 5 investigated 146 men with localized, advanced and metastatic PC, respectively, and found a Gleason score X8, positive lymph nodes or metastatic disease, and age o70 years as the strongest predictors of biochemical progression. Variables with larger w 2 were more significant.
Molecular markers during IAS H Augustin et al
The limited number of studies addressing molecular changes during IAS triggered our interest in this piece of work, but the data suggest that clinical parameters rather than biological markers are more useful for appropriately selecting patients for IAS. However, a limitation exists to the present study owing to the small number of patients and the possible methodological problems as mentioned above.
Conclusion
During IAS, a significant change in the expression of biomolecular markers was only seen for Ki-67. However, none of the biomarkers showed a significant correlation with the first off-treatment time. Pretreatment PSA, testosterone recovery time and initial biopsy grade correlated with off-treatment time in a univariate analysis; however, only the latter remained an independent predictor in the multivariate analysis. We conclude that off-treatment time during IAS is best predicted by clinical parameters and biomolecular markers from needle biopsies do not further contribute to a better patient selection.
